Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -450.70K | -499.20K | -491.10K | -526.20K | -599.20K |
| Total Depreciation and Amortization | 24.30K | 24.20K | 24.50K | 24.90K | 25.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.50K | 23.50K | 17.10K | 15.00K | 23.60K |
| Change in Net Operating Assets | 154.30K | -64.50K | 62.50K | -176.90K | 65.30K |
| Cash from Operations | -255.70K | -516.00K | -387.00K | -663.10K | -484.40K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 371.90K | 550.00K | 635.40K | 1.00M | 770.00K |
| Total Debt Repaid | -41.90K | -41.90K | -41.90K | -39.70K | -38.60K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 242.00K | 371.30K | 440.20K | 705.80K | 545.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.70K | -144.70K | 53.30K | 42.80K | 60.90K |
